FIELD: biotechnology.
SUBSTANCE: invention relates to a human isolated natural killer cell (NK cell) in a cryopreserved state. Said cell is intended for producing an NK cell capable of exhibiting a cytotoxic effect on a target cell, and is pre-loaded before freezing with an antibody construct comprising a first binding domain binding to an NK cell receptor antigen on the cell surface of an immunological effector cell, and a second binding domain binding to the cell surface antigen on the cell surface of the target cell. Said first and second binding domains contain three light chain CDRs and three heavy chain CDRs. Present invention also relates to methods of producing NK cells, a pharmaceutical composition and a method of treating a tumor disease.
EFFECT: present invention enables to maintain the antibody structure in a state bound to the cell surface even during and after the NK cell is in a cryopreserved state.
29 cl, 9 dwg, 6 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
RECOVERED ANTIBODY (VERSIONS), A METHOD FOR PRODUCING THE ANTIBODY, AN ISOLATED NUCLEIC ACID, AN EXPRESSION CASSETTE (VERSIONS), A PLASMID (VERSIONS), A HOST CELL, A PHARMACEUTICAL PREPARATION, A KIT, A METHOD OF TREATING A PATIENT, AT RISK OF OR SUFFERING FROM ESCHERICHIA COLI INFECTION, AND A DIAGNOSTIC TECHNIQUE FOR DETERMINING ESCHERICHIA COLI INFECTIONS | 2014 |
|
RU2724530C2 |
ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
Authors
Dates
2024-05-28—Published
2019-08-26—Filed